Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.
Current Medicinal Chemistry
Title:Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Volume: 24 Issue: 20
Author(s): Sandra M. Martín-Guerrero, Josefa León, Rosa Quiles-Perez, Laura Belmonte, David Martin-Oliva, Ángeles Ruiz-Extremera, Javier Salmerón and José Antonio Muñoz-Gámez*
Affiliation:
- Laboratory of Medical Research, Clinical Management Unit of Digestive Disease, San Cecilio University Hospital, Avda de Madrid s/n, 18012, Granada,Spain
Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.
Abstract: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
Export Options
About this article
Cite this article as:
Martín-Guerrero M. Sandra, León Josefa , Quiles-Perez Rosa , Belmonte Laura, Martin-Oliva David , Ruiz-Extremera Ángeles, Salmerón Javier and Muñoz-Gámez Antonio José *, Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement, Current Medicinal Chemistry 2017; 24 (20) . https://dx.doi.org/10.2174/0929867324666170316115039
DOI https://dx.doi.org/10.2174/0929867324666170316115039 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Current Pharmaceutical Design Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Biomimetic Mineralization of Tumor Targeted Ferromagnetic Iron Oxide Nanoparticles Used for Media of Magnetic Hyperthermia
Current Drug Delivery Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies
Current Medicinal Chemistry Antiangiogenic Triterpenes Isolated from Chinese Herbal Medicine Actinidia chinensis Planch
Anti-Cancer Agents in Medicinal Chemistry Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets A Validated HPLC-PDA Method for the Analysis of Ursolic Acid Content in Poly(lactic acid) Nanoparticles
Current Chromatography NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design